Elanco Animal Health Incorporated Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Elanco Animal Health Incorporated share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 100.00K shares.
- Elanco Animal Health Incorporated share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 0.00 shares.
- Elanco Animal Health Incorporated share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 0.00 shares.
- Elanco Animal Health Incorporated share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2020 was 0.00 shares, a 100.00% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 100.00K shares 10-K · filed 2026-02-24 | |
| 2023-12-31 | 0.00 shares 10-K · filed 2024-02-26 | |
| 2022-12-31 | 0.00 shares 10-K · filed 2023-03-01 | |
| 2020-12-31 | 0.00 shares 10-K · filed 2021-03-01 | |
| 2019-12-31 | 100.00K shares 10-K · filed 2020-02-28 | |
| 2018-12-31 | 0.00 shares 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |